비바이러스성 형질 전환 시약 시장(제3판) : 비바이러스성 트랜스펙션 방법, 용도, 최종사용자, 지역별 동향 및 예측(-2035년)

NON-VIRAL TRANSFECTION REAGENTS MARKET: OVERVIEW

As per Roots Analysis, the global non-viral transfection reagents market is estimated to grow from 0.89 billion in the current year to USD 2.01 billion by 2035, at a CAGR of 9.5% during the forecast period, till 2035.

NON-VIRAL TRANSFECTION REAGENTS MARKET: GROWTH AND TRENDS

Nucleic acid-based therapies have demonstrated significant potential in targeting genetic mechanisms for the treatment of a broad range of therapeutic indications. Consequently, a growing number of these therapies have secured regulatory approvals, underscoring both their clinical potential and the increasing adoption of this therapeutic class.

The expanding pipeline and commercialization of nucleic acid-based therapeutics have accelerated the demand for efficient delivery platforms capable of ensuring targeted and effective intracellular delivery. Traditionally, the development and manufacturing of such therapies have relied heavily on viral vectors. However, despite substantial advancements in viral vector research and manufacturing capabilities, several limitations continue to hinder their widespread applicability.

Key challenges associated with viral vectors include immunogenicity and cytotoxicity concerns, high development and manufacturing costs, and limitations related to the quantity of genetic material that can be delivered per dose. In response to these constraints, industry stakeholders are increasingly transitioning toward non-viral gene delivery technologies for transfection applications.

Non-viral transfection systems involve the targeted delivery of genetic material into a diverse range of cell types using non-viral vectors as delivery carriers. To address the growing demand for nucleic acid-based therapeutics, companies are actively developing advanced non-viral transfection reagents and systems that are highly suitable for in vitro intracellular delivery applications. Furthermore, driven by the rising preference for non-viral vectors and ongoing technological advancements in transfection reagents and systems, the non-viral transfection reagents market is anticipated to witness steady growth in the coming years.

Growth Drivers: Strategic Enablers of Market Expansion

The non-viral transfection reagents market is primarily driven by the growing demand for nucleic acid-based therapeutics, including gene therapies, mRNA therapeutics, RNAi-based drugs, and DNA vaccines, which require efficient intracellular delivery technologies. In addition, the limitations associated with viral vectors, such as immunogenicity, cytotoxicity, high manufacturing costs, and limited cargo capacity, are encouraging the adoption of non-viral delivery systems as safer and more scalable alternatives. The market is further supported by increasing research activities in cell and gene therapy, rising investments in biotechnology and pharmaceutical R&D, and the expanding adoption of gene editing technologies such as CRISPR-Cas9. Moreover, continuous technological advancements in lipid-based, polymer-based, and nanoparticle-based transfection systems have enhanced delivery efficiency and cell viability, thereby accelerating market adoption across research and therapeutic applications.

Market Challenges: Critical Barriers Impeding Progress

The non-viral transfection reagents market faces several challenges despite its growing adoption across research and therapeutic applications. One of the primary concerns is the relatively lower transfection efficiency of non-viral systems compared to viral vectors, particularly in hard-to-transfect and primary cell types. In addition, issues related to limited intracellular uptake, reduced stability of genetic material, transient gene expression, and potential cytotoxic effects of certain reagents continue to hinder widespread application. The lack of standardized protocols and variability in transfection performance across different cell lines further complicate product adoption in both research and clinical settings. Moreover, the development of highly efficient and targeted non-viral delivery systems requires substantial investment in research and optimization, increasing overall development costs. Regulatory complexities associated with advanced gene delivery technologies and the growing competition from emerging delivery platforms also pose significant challenges to market growth.

NON-VIRAL TRANSFECTION REAGENTS MARKET: KEY TRENDS

The report delves into the current state of the non-viral transfection reagents market and identifies potential growth opportunities within industry. Some key highlights in this domain include:

Rising Prevalence of Chronic Diseases: The increasing prevalence of chronic diseases has accelerated the demand for innovative and potentially curative therapeutic interventions, thereby driving the adoption of non-viral transfection reagents and systems. The growing preference for non-viral transfection technologies can be attributed to the multiple advantages they offer, including enhanced therapeutic efficacy through targeted and localized delivery while minimizing systemic exposure. As a result, these technologies have the potential to improve treatment outcomes and enhance patient quality of life across various therapeutic applications.

Advancements in Nanotechnology and Biotechnology: Continuous advancements in nanotechnology and biotechnology have enabled the developers to improve drug efficacy and delivery precision. Advanced nanomaterials facilitate targeted intracellular delivery while reducing systemic side effects, owing to their multifunctional design capabilities that allow the incorporation of targeting ligands and therapeutic payloads. Several non-viral transfection reagents leveraging nanotechnology-based delivery carriers have emerged in the market, including products such as jetOPTIMUS and PolyMag.

Non-Viral Transfection Reagents Market

The market sizing and opportunity analysis has been segmented across the following parameters:

Market by Type of Non-Viral Transfection Method

• Chemical Methods
• Physical Methods
• Other Methods

Market by Application Area

• Research Applications
• Clinical Applications

Market by End-User

• Veterinary Academic and Research Institutions
• Pharmaceutical and Biotechnological Companies
• Contract Manufacturers
• Other End-users

Market by Geographical Regions

• North America
  • US
  • Canada
• Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • Australia
  • South Korea
  • China
  • Rest of Asia-Pacific
• Middle East and Africa
  • Saudi Arabia
  • UAE
  • Egypt
• Rest of Middle East and Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

NON-VIRAL TRANSFECTION REAGENTS MARKET: KEY SEGMENTS

Which Type of Non-Viral Transfection Method Accounts for the Largest Share of the Non-Viral Transfection Reagents and Equipment Market?

The non-viral transfection reagents and equipment market is segmented based on the type of non-viral transfection method into chemical methods, physical methods, and other methods. According to the non-viral transfection reagents market analysis, the chemical methods segment captures nearly 60% of the overall market share. This dominance can be attributed to the increasing adoption of primary cell transfection reagents and non-viral vectors in gene therapy applications across the global market.

The physical methods segment is anticipated to witness a comparatively higher CAGR during the forecast period, driven by ongoing technological advancements in techniques such as electroporation. These technologies offer several advantages, including shorter transfection timelines, improved biological efficiency, lower toxicity, and enhanced versatility for nucleic acid delivery across a broad range of cell types.

Regional Analysis: Which Regions are Demonstrating the Fastest Growth in the Non-Viral Transfection Reagents Industry?

North America: Largest Regional Market

North America represents approximately 60% of the global non-viral transfection reagents market share. The region's leadership position is supported by its well-established pharmaceutical and biotechnology industry, coupled with the rapid adoption of advanced non-viral transfection technologies. Moreover, North America serves as a major hub for companies involved in the development of complex biologics and advanced therapeutics, including cell and gene therapies, thereby generating significant demand for locally manufactured non-viral transfection reagents and systems, particularly due to their limited shelf life and specialized handling requirements.

US Non-Viral Transfection Reagents Market Trends

In the US, supportive regulatory pathways established by the US Food and Drug Administration for the approval of DNA transfection reagents, RNA transfection reagents, and non-viral transfection technologies are contributing significantly to market growth. Although regulatory standards remain stringent, the availability of clear regulatory guidance for validation and commercialization has facilitated broader adoption and accelerated market entry for innovative transfection systems.

Asia-Pacific: Emerging as a Key Growth Hub

The Asia-Pacific non-viral transfection reagents market is anticipated to witness the highest CAGR through 2035. This growth is primarily driven by the region's expanding large-scale manufacturing capabilities for active pharmaceutical ingredients (APIs) and the increasing outsourcing of high-value biologics manufacturing activities. In order to comply with global quality and export standards, regional manufacturers are making significant investments in advanced manufacturing infrastructure and increasingly adopting non-viral transfection reagents and systems across research and production workflows.

Will the Research Applications Segment Continue to Hold the Largest Market Share?

According to the non-viral transfection reagents market forecast, the research applications segment currently represents the largest share of the market. This dominance can be attributed to the growing focus on research and development activities, along with the increasing adoption of non-viral transfection methods across molecular biology, cell biology, and gene therapy research applications. Meanwhile, the clinical applications segment is expected to register a higher CAGR during the forecast period. The rising prevalence of chronic diseases, coupled with the increasing number of approvals for cell and gene therapies, is anticipated to drive the growth of this segment over the coming years.

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

• Former-Vice-President, Business Development and Partnerships, Small Company, US
• Former Global Business Development Manager, Clinical Operations, Mid-sized Company, France
• Researcher, Mid-sized Non-Industry Player, Chile

Additionally, the market report includes transcripts of the following third-party discussions:

• Chairman and Chief Executive Officer, Mid-sized Company, the US
• Co-Founder and Chief Executive Officer, Small Company, the US
• Chief Scientific Officer and Executive Vice President of R&D, Mid-sized Company, the US
• Chief Scientific Officer, Mid-sized Company, the US
• Vice President of Cell Therapy Process Development, Large Company, the US
• Group Leader of R&D Transfection, and Director and Senior Product Manager, Large Company, Switzerland

Example Players in Non-Viral Transfection Reagents Market

• BEX
• Bio-Rad Laboratories
• Harvard Bioscience
• LocateBio
• MaxCyte
• MilliporeSigma
• Nepa Gene
• N4 Pharma
• OZ Biosciences
• Thermo Fisher Scientific

NON-VIRAL TRANSFECTION REAGENTS MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global non-viral transfection reagents market, focusing on key market segments, including [A] type of non-viral transfection method, [B] application area, [C] end-user and [D] key geographical regions.
• Non-Viral Transfection Reagents Market Landscape: A comprehensive evaluation of the companies developing non-viral transfection reagents, based on several relevant parameters, such as [A] type of carrier used, [B] compatible cell type, [C] type of molecule delivered and [D] serum compatibility. Additionally, a comprehensive evaluation of non-viral transfection reagent developers, based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
• Electroporation-Based Transfection Systems Market Landscape: A detailed analysis of the companies developing electroporation-based non-viral transfection systems, based on several relevant parameters, such as [A] compatible cell type and [B] type of molecule delivered. Additionally, a comprehensive evaluation of electroporation transfection systems developers, based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
• Other Non-Viral Transfection Systems Market Landscape: An insightful evaluation of the companies developing other non-viral transfection systems, based on several relevant parameters, such as [A] compatible cell type and [B] type of molecule delivered. Additionally, a comprehensive evaluation of other non-viral transfection systems developers, based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
• Company Competitiveness Analysis: A comprehensive competitive analysis of non-viral transfection reagent and system developers, examining factors, such as [A] developer strength and [B] product portfolio strength.
• Technology Competitiveness Analysis: A detailed analysis of electroporation transfection systems and other non-viral transfection systems, examining factors, such as [A] developer strength and [B] product portfolio strength.
• Company Profiles: In-depth profiles of key players that are engaged in the development of non-viral transfection reagents and systems, focusing on [A] overview of the company, [B] financial information (if available) and [C] recent developments and an informed future outlook.
• Potential Strategic Partners: An insightful analysis of more than 80 cell and gene therapy developers that are likely to partner with non-viral transfection reagent and system developers, based on several relevant parameters, such as [A] pipeline maturity, [B] developer strength, [C] pipeline strength and [D] type of therapy.
• Benchmark Analysis: A comprehensive benchmark analysis of various non-viral focused initiatives undertaken by big pharma players, based on several relevant parameters, such as [A] year of initiative, [B] type of initiative, [C] type of therapy and [D] target therapeutic area.
• Patent Analysis: An in-depth analysis of patents filed / granted till date in the non-viral transfection systems domain, based on various relevant parameters, such as [A] type of patent, [B] publication year, [C] application year, [D] geography, [E] type of applicant, [F] CPC symbols, [G] emerging focus areas, [H] leading players (in terms of number of patents granted / filed), [I] patent benchmarking and [J] valuation analysis.
• Publication Analysis: An insightful analysis of over 450 peer-reviewed, scientific articles focused on non-viral transfection reagents and systems, based on various relevant parameters, such as [A] year of publication, [B] type of publication, [C] type of molecule delivered, [D] target therapeutic area, [E] key focus areas, [F] popular cells and cell lines. Additionally, the section includes analysis of the leading publishers across different geographies and key journals (in terms of number of articles published).
• Roots Analysis Pricing Strategy Framework: A detailed framework for analyzing the pricing strategy of a company's non-viral transfection reagents and its competitive market position, including an equation to estimate reagent prices based on their characteristics.
• Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

• Which are the leading companies in the non-viral transfection reagents market?
• Which region dominates the non-viral transfection reagents market?
• What are the key trends observed in non-viral transfection reagents market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by non-viral transfection reagents providers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

ADDITIONAL BENEFITS

• Complementary PPT Insights Pack
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Report Coverage
• 1.3. Market Segmentation
• 1.4. Key Market Insights
• 1.5. Market Share Insights
• 1.6. Key Questions Asked

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

• 5.1. Executive Summary: Market Landscape
• 5.2. Executive Summary: Market Trends
• 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Introduction to Transfection
• 6.3. Methods of Transfection
  • 6.3.1. Virus Based Transfection
    • 6.3.1.1. Types of Viral Transfection Vectors
      • 6.3.1.1.1. Adeno-associated Virus-based Vectors
      • 6.3.1.1.2. Adenovirus-based Vectors
      • 6.3.1.1.3. Herpes Virus-based Vectors
      • 6.3.1.1.4. Lentivirus-based Vectors
      • 6.3.1.1.5. Retrovirus-based Vectors
  • 6.3.2. Non-Virus Based Transfections
    • 6.3.2.1. Chemical Methods based Transfection
      • 6.3.2.1.1. Lipoplexes-based Transfection
      • 6.3.2.1.2. Polyplexes-based Transfection
      • 6.3.2.1.3. Lipo-polyplexes-based Transfection
      • 6.3.2.1.4. Dendrimer-based Transfection
      • 6.3.2.1.5. Cell Penetrating Peptide-based Transfection
    • 6.3.2.2. Physical Method based Transfections
      • 6.3.2.2.1. Electroporation-based Transfection
      • 6.3.2.2.2. Gene Gun-based Transfection
      • 6.3.2.2.3. Sonoporation-based Transfection
      • 6.3.2.2.4. Microinjection-based Transfection
      • 6.3.2.2.5. Magnetofection-based Transfection
• 6.4. Applications of Transfection
  • 6.4.1. Advanced Therapeutic Medicinal Product Development
  • 6.4.2. Gene Silencing
  • 6.4.3. Generation of Stable Cell Lines
  • 6.4.4. Large-scale Protein Production
  • 6.4.5. Stem Cell Engineering
• 6.5. Future Perspective

7. MARKET LANDSCAPE: NON-VIRAL TRANSFECTION REAGENTS

• 7.1. Chapter Overview
• 7.2. Non-Viral Transfection Reagents: Overall Market Landscape
  • 7.2.1. Analysis by Compatible Cell Type / Line
  • 7.2.2. Analysis by Transfected Molecule
  • 7.2.3. Analysis by Type of Transfection Carrier Used
  • 7.2.4. Analysis by Type of Cell Culture
  • 7.2.5. Analysis by Serum Compatibility
• 7.3. Non-Viral Transfection Reagent Providers Landscape
  • 7.3.1. Analysis by Year of Establishment
  • 7.3.2. Analysis by Company Size
  • 7.3.3. Analysis by Location of Headquarters

8. MARKET LANDSCAPE: ELECTROPORATION-BASED TRANSFECTION SYSTEMS

• 8.1. Chapter Overview
• 8.2. Electroporation-based Transfection Systems: Overall Market Landscape
  • 8.2.1. Analysis by Compatible Cell Type / Line
  • 8.2.2. Analysis by Transfected Molecule
  • 8.2.3. Analysis by Type of Waveform
  • 8.2.4. Analysis by Pulse Voltage
• 8.3. Electroporation-based Transfection System Providers Landscape
  • 8.3.1. Analysis by Year of Establishment
  • 8.3.2. Analysis by Company Size
  • 8.3.3. Analysis by Location of Headquarters
  • 8.3.4. Analysis by Leading Players

9. MARKET LANDSCAPE: OTHER NON-VIRAL TRANSFECTION TECHNOLOGIES / SYSTEMS

• 9.1. Chapter Overview
• 9.2. Other Non-Viral Transfection Technologies / Systems: Market Landscape
  • 9.2.1. Analysis by Type of Offering
  • 9.2.2. Analysis by Compatible Cell Type / Line
  • 9.2.3. Analysis by Transfected Molecule
• 9.3. Other Non-Viral Transfection Technologies / System Providers Landscape
  • 9.3.1. Analysis by Year of Establishment
  • 9.3.2. Analysis by Company Size
  • 9.3.3. Analysis by Location of Headquarters

10. COMPANY COMPETITIVENESS ANALYSIS

• 10.1. Chapter Overview
• 10.2. Assumptions and Key Parameters
• 10.3. Methodology
• 10.4. Company Competitiveness Analysis: Non-Viral Transfection Reagent Providers
  • 10.4.1. Non-Viral Transfection Reagent Providers based in North America (Peer Group I)
  • 10.4.2. Non-Viral Transfection Reagent Providers based in Europe (Peer Group II)
  • 10.4.3. Non-Viral Transfection Reagent Providers based in Asia-Pacific (Peer Group III)

11. TECHNOLOGY COMPETITIVENESS ANALYSIS

• 11.1. Chapter Overview
• 11.2. Assumptions and Key Parameters
• 11.3. Methodology
• 11.4. Technology Competitiveness Analysis: Electroporation-based Transfection Systems
  • 11.4.1. Electroporation-based Transfection Systems Offered by Players based in North America (Peer Group I)
  • 11.4.2. Electroporation-based Transfection Systems Offered by Players based in Europe and Asia-Pacific (Peer Group II)
• 11.5. Technology Competitiveness Analysis: Other Non-Viral Transfection Technology / Systems
  • 11.5.1. Other Non-Viral Transfection Technologies / Systems Offered by Players based in North America (Peer Group I)
  • 11.5.2. Other Non-Viral Transfection Technologies / Systems Offered by Players based in Europe and Asia-Pacific (Peer Group II)

12. COMPANY PROFILES

• 12.1. Chapter Overview
• 12.2. Non-Viral Transfection Reagent Providers
  • 12.2.1. MilliporeSigma
    • 12.2.1.1. Company Overview
    • 12.2.1.2. Financial Information
    • 12.2.1.3. Non-Viral Transfection Reagents Portfolio
    • 12.2.1.4. Recent Developments and Future Outlook
  • 12.2.2. OZ Biosciences
    • 12.2.2.1. Company Overview
    • 12.2.2.2. Non-Viral Transfection Reagents Portfolio
    • 12.2.2.3. Recent Developments and Future Outlook
  • 12.2.3. Thermo Fisher Scientific
    • 12.2.3.1. Company Overview
    • 12.2.3.2. Financial Information
    • 12.2.3.3. Non-Viral Transfection Reagents Portfolio
    • 12.2.3.4. Recent Development and Future Outlook
• 12.3. Electroporation-based Non-Viral Transfection System Providers
  • 12.3.1. BEX
    • 12.3.1.1. Company Overview
    • 12.3.1.2. Electroporation-based Non-Viral Transfection System Portfolio
    • 12.3.1.3. Recent Developments and Future Outlook
  • 12.3.2. Bio-Rad Laboratories
    • 12.3.2.1. Company Overview
    • 12.3.2.2. Financial Information
    • 12.3.2.3. Electroporation-based Non-Viral Transfection System Portfolio
    • 12.3.2.4. Recent Developments and Future Outlook
  • 12.3.3. Harvard Bioscience
    • 12.3.3.1. Company Overview
    • 12.3.3.2. Financial Information
    • 12.3.3.3. Electroporation-based Non-Viral Transfection System Portfolio
    • 12.3.3.4. Recent Developments and Future Outlook
  • 12.3.4. MaxCyte
    • 12.3.4.1. Company Overview
    • 12.3.4.2. Financial Information
    • 12.3.4.3. Electroporation-based Non-Viral Transfection System Portfolio
    • 12.3.4.4. Recent Developments and Future Outlook
  • 12.3.5. NepaGene
    • 12.3.5.1. Company Overview
    • 12.3.5.2. Electroporation-based Non-Viral Transfection System Portfolio
    • 12.3.5.3. Recent Developments and Future Outlook
• 12.4. Other Non-Viral Transfection Technology / System Providers
  • 12.4.1. LocateBio
    • 12.4.1.1. Company Overview
    • 12.4.1.2. Other Non-Viral Transfection Technology / System Portfolio
    • 12.4.1.3. Recent Developments and Future Outlook
  • 12.4.2. N4 Pharma
    • 12.4.2.1. Company Overview
    • 12.4.2.2. Other Non-Viral Transfection Technology / System Portfolio
    • 12.4.2.3. Recent Developments and Future Outlook

13. POTENTIAL STRATEGIC PARTNERS

• 13.1. Chapter Overview
• 13.2. Assumptions and Key Parameters
• 13.3. Scope and Methodology
• 13.4. Potential Strategic Partners for Non-Viral Transfection Reagents and Systems Providers based in North America
  • 13.4.1. Most Likely Partners
  • 13.4.2. Likely Partners
  • 13.4.3. Less Likely Partners
  • 13.4.4. Least Likely Partners
• 13.5. Potential Strategic Partners for Non-Viral Transfection Reagents and Systems Providers based in Europe
  • 13.5.1. Most Likely Partners
  • 13.5.2. Likely Partners
  • 13.5.3. Less Likely Partners
  • 13.5.4. Least Likely Partners
• 13.6. Potential Strategic Partners for Non-Viral Transfection Reagents and Systems Providers based in Asia-Pacific and Rest of the World
  • 13.6.1. Most Likely Partners
  • 13.6.2. Likely Partners
  • 13.6.3. Less Likely Partners
  • 13.6.4. Least Likely Partners

14. MARKET TRENDS ANALYSIS

• 14.1. Chapter Overview
• 14.2. Ex-vivo and In-vivo Therapy Trends
• 14.3. Viral and Non-Viral Vector Trends

15. PATENT ANALYSIS

• 15.1. Chapter Overview
• 15.2. Scope and Methodology
• 15.3. Non-Viral Transfection: Patent Analysis
  • 15.3.1. Analysis by Patent Publication Year
  • 15.3.2. Analysis by Type of Patent and Publication Year
  • 15.3.3. Analysis by Patent Application Year
  • 15.3.4. Analysis by Patent Jurisdiction
  • 15.3.5. Analysis by CPC Symbols
  • 15.3.6. Analysis by Type of Applicant
  • 15.3.7. Leading Players: Analysis by Number of Patents
  • 15.3.8. Leading Inventors: Analysis by Number of Patents
• 15.4. Patent Benchmarking Analysis
  • 15.4.1. Analysis by Patent Characteristics
• 15.5. Patent Valuation

16. PUBLICATION ANALYSIS

• 16.1. Chapter Overview
• 16.2. Scope and Methodology
• 16.3. Non-Viral Transfection Reagents and Systems: Publication Analysis
  • 16.3.1. Analysis by Year of Publication
  • 16.3.2. Most Active Publisher: Analysis by Number of Publications
  • 16.3.3. Key Journals: Analysis by Journal Impact Factor
  • 16.3.4. Most Popular Journals: Analysis by Number of Publications
• 16.4. Prominent Copyright Holders: Analysis by Number of Publications

17. ROOTS ANALYSIS PRICING STRATEGY FRAMEWORK

• 17.1. Chapter Overview
• 17.2. Roots Analysis Framework
  • 17.2.1. Methodology
  • 17.2.2. Theoretical Framework and Price Evaluation Hypothesis
  • 17.2.3. Results and Interpretation
    • 17.2.3.1. Product Price Evaluation Matrix: Based on Transfection Efficiency
    • 17.2.3.2. Product Price Evaluation Matrix: Based on Compatible Cell Type / Line
    • 17.2.3.3. Product Price Evaluation Matrix: Based on Type of Carrier Used
    • 17.2.3.4. Product Price Evaluation Matrix: Based on Type of Molecule Delivered
    • 17.2.3.5. Product Price Evaluation Matrix: Based on Type of Reagent
• 17.3. Concluding Remarks

18. MARKET IMPACT ANALYSIS

• 18.1. Chapter Overview
• 18.2. Market Drivers
• 18.3. Market Restraints
• 18.4. Market Opportunities
• 18.5. Market Challenges

19. GLOBAL NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Global Non-Viral Transfection Reagents and Systems Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 19.3.1. Scenario Analysis
    • 19.3.1.1. Conservative Scenario
    • 19.3.1.2. Optimistic Scenario
• 19.4. Key Market Segmentations

20. NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET, BY TYPE OF TRANSFECTION METHOD

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Non-Viral Transfection Reagents and Systems Market: Distribution by Type of Transfection Method
  • 20.3.1. Non-Viral Transfection Reagents and Systems Market for Chemical Methods, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 20.3.2. Non-Viral Transfection Reagents and Systems Market for Physical Methods, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 20.3.3. Non-Viral Transfection Reagents and Systems Market for Other Methods, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
• 20.4. Data Triangulation and Validation

21. NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET, BY APPLICATION AREA

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Non-Viral Transfection Reagents and Systems Market: Distribution by Application Area
  • 21.3.1. Non-Viral Transfection Reagents and Systems Market for Research Applications, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 21.3.2. Non-Viral Transfection Reagents and Systems Market for Clinical Applications, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
• 21.4. Data Triangulation and Validation

22. NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET, BY END-USER

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Non-Viral Transfection Reagents and Systems Market: Distribution by End-User
  • 22.3.1. Non-Viral Transfection Reagents and Systems Market for Academic and Research Institutes, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 22.3.2. Non-Viral Transfection Reagents and Systems Market for Pharmaceutical and Biopharmaceutical Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 22.3.3. Non-Viral Transfection Reagents and Systems Market for Contract Manufacturers, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 22.3.4. Non-Viral Transfection Reagents and Systems Market for Other End-Users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
• 22.4. Data Triangulation and Validation

23. NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET, BY KEY GEOGRAPHICAL REGIONS

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Non-Viral Transfection Reagents and Systems Market: Distribution by Geographical Regions
  • 23.3.1. Non-Viral Transfection Reagents and Systems Market in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.1.1. Non-Viral Transfection Reagents and Systems Market in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.1.2. Non-Viral Transfection Reagents and Systems Market in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 23.3.2. Non-Viral Transfection Reagents and Systems Market in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.2.1. Non-Viral Transfection Reagents and Systems Market in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.2.2. Non-Viral Transfection Reagents and Systems Market in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.2.3. Non-Viral Transfection Reagents and Systems Market in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.2.4. Non-Viral Transfection Reagents and Systems Market in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.2.5. Non-Viral Transfection Reagents and Systems Market in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.2.6. Non-Viral Transfection Reagents and Systems Market in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 23.3.3. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.3.1. Non-Viral Transfection Reagents and Systems Market in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.3.2. Non-Viral Transfection Reagents and Systems Market in Australia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.3.3. Non-Viral Transfection Reagents and Systems Market in South Korea, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.3.4. Non-Viral Transfection Reagents and Systems Market in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.3.5. Non-Viral Transfection Reagents and Systems Market in Rest of Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 23.3.4. Non-Viral Transfection Reagents and Systems Market in Middle East and Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.4.1. Non-Viral Transfection Reagents and Systems Market in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.4.2. Non-Viral Transfection Reagents and Systems Market in UAE, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.4.3. Non-Viral Transfection Reagents and Systems Market in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.4.4. Non-Viral Transfection Reagents and Systems Market in Rest of Middle East and Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 23.3.5. Non-Viral Transfection Reagents and Systems Market in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.5.1. Non-Viral Transfection Reagents and Systems Market in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.5.2. Non-Viral Transfection Reagents and Systems Market in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 23.3.5.3. Non-Viral Transfection Reagents and Systems Market in Rest of Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
• 23.4. Market Dynamics Assessment
  • 23.4.1. Market Movement Analysis
  • 23.4.2. Penetration-Growth (P-G) Matrix
• 23.5. Data Triangulation and Validation

24. CONCLUDING REMARKS

25. EXECUTIVE INSIGHTS

• 25.1. Chapter Overview
• 25.2. Company A
  • 25.2.1. Interview Transcript: Former Vice President, Business Development and Partnerships
• 25.3. Company B
  • 25.3.1. Interview Transcript: Former Global Business Development Manager, Clinical Operations
• 25.4. Company C
  • 25.4.1. Interview Transcript: Researcher

26. APPENDIX I: TABULATED DATA

27. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS